Healthcare / Drug Manufacturers - Specialty & GenericNasdaqGS
$2.03
-0.09 (-4.25%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $1.2M · quality 46.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$23M
P/E
203.0x
↑EV/EBITDA
N/A
•ROE
-2.1%
↓Gross Margin
N/A
•Debt/Equity
0.23
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
81.2%
FCF / Net income
-4.31x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.0M · net income $-569000.0 · FCF $2.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | $3.0M | $3.0M | $1.8M | $1.3M | $70.0M | $2.6M | $64.9M | $49.6M | $16.1M | $16.8M | $19.4M | $20.1M | $15.0M | $8.8M | $3.8M | $2.1M | — |
| Net Income | $-569000.00 | $-569000.00 | $-2.2M | $-10.3M | $112.0M | $-172.4M | $-183.5M | $-176.1M | $-132.6M | $-76.9M | $-89.9M | $-85.1M | $-54.2M | $-28.4M | $-35.1M | $-12.9M | $-2.9M |
| EBITDA | $-3.0M | $-3.0M | $-3.6M | $-7.6M | $11.9M | $-78.8M | $-151.5M | $-149.8M | $-129.9M | $-77.4M | $-90.1M | $-85.1M | $-54.0M | $-25.8M | $-16.1M | $-5.4M | — |
| EPS | — | — | -0.19 | -0.98 | 11.96 | -21.66 | — | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | 100.0% | 98.0% | 45.5% | 75.4% | 87.2% | 83.0% | 84.3% | 78.4% | 77.6% | 75.6% | 77.7% | 64.7% | 54.6% | — |
| Operating Margin | -139.4% | -139.4% | -275.1% | -654.6% | 15.2% | -3092.8% | -239.8% | -304.6% | -808.8% | -462.7% | -466.3% | -422.9% | -359.6% | -294.1% | -423.0% | -259.9% | — |
| Net Margin | -18.8% | -18.8% | -123.9% | -789.4% | 160.1% | -6700.9% | -282.9% | -354.8% | -823.7% | -458.5% | -464.3% | -422.4% | -360.8% | -323.8% | -919.9% | -618.4% | — |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | 0.23 | 0.23 | 0.26 | 0.27 | 0.25 | 0.00 | -1.92 | 21.15 | 0.75 | — | — | — | — | — | — | — | — |
| Current Ratio | 3.11 | 3.11 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $2.5M | $2.5M | $1.2M | $-23.1M | $9.0M | $-142.7M | $-159.7M | $-168.2M | $-107.0M | $-76.2M | $-69.5M | $-79.2M | $-45.6M | $-20.8M | $-12.8M | $-5.0M | — |
| Returns | |||||||||||||||||
| ROE | -2.1% | -2.1% | -8.0% | -35.1% | 318.7% | 184.2% | 148.0% | -1914.4% | -136.0% | -59.2% | -70.5% | -134.9% | -112.0% | -52.0% | 2450.6% | 754.3% | — |
| Valuation | |||||||||||||||||
| P/E | 203.00 | 203.00 | — | — | 0.46 | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | — | — | — | — | 1.87 | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 0.87 | 0.87 | 0.62 | 0.81 | 1.47 | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | 71.6% | 71.6% | 35.3% | -98.1% | — | -96.0% | 30.7% | 208.4% | -4.0% | -13.3% | -3.9% | 34.1% | 71.2% | 129.8% | 82.8% | — | — |
| EPS Growth | — | — | 80.6% | -108.2% | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+84.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.19 → n/d
Residual
+84.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.